Background: Nitrendipine is prescribed to children for the treatment of primary hypertension (off-label use). Available specialties (Nidrel
Introduction
Nitrendipine is a dihydropyridine calcium channel blocker used in treatment of primary hypertension. When the drug is absorbed, it diffuses into smooth muscle cells membrane and inactivate L-type calcium channel [1] . The reduced levels of calcium prevent smooth muscle contraction and dilation of the vasculature reduces total peripheral resistance, which decreases blood pressure.
Although it was an unlicensed drug, nitrendipine is widely used in pediatrics. The daily dose of nitrendipine used in children is in the range of 1-3 mg per kg, two or three times daily. Available specialties (Nidrel ® , 10 or 20 mg; Baypress ® 10 mg and others generic drugs) are only marketed in tablet form, which is unsuitable for pediatric use because younger children are unable to swallow tablets. Moreover, available dosages do not allow obtaining low dosages precisely.
In the absence of a ready-made product, a hospital preparation of nitrendipine oral suspension at 5 mg/mL was developed. The suspending vehicle selected was Syrspend ® SF PH4 because this suspension base has many benefits: ready-to-use, buffered to pH 4.2 for maximum active pharmaceutical ingredient (API) compatibility, gently preserved with < 0.1 % sodium benzoate which is suitable for pediatrics, low osmolality (compatible with common enteral feeding tube). Syrspend SF PH4 is sugar free and suitable for diabetics or children treated with a ketogenic diet. In addition, this cherry flavored suspending vehicle masks the unpleasant taste of nitrendipine powder. However, there were no data about nitrendipine stability in the suspending vehicle, Syrspend ® SF PH4 [2] .
A stability study was carried out according to the recommendations of the International Conference on Harmonization (ICH) to set a shelf life in order to deliver the drug product to patients with quality and safety [3] . The purpose of this study was to determine physicochemical and microbiological stability of the oral suspension. Many of analytical methods for nitrendipine in biological samples were reported in the scientific literature [4, 56] but not for assay in hospital preparation. Moreover, there were some problems for reproducing those methods in our laboratory: different instrumentation, economic reasons and unavailable reagents. For these reasons, we decided to develop and to validate a high-performance liquid chromatographic (HPLC) method for the assay of nitrendipine.
Materials and methods

Reagents
Nitrendipine (Nidrel ® ) 20 mg tablets were bought to UCB Pharma (Colombes, France) and Syrspend ® SF PH4 to Fagron (Thiais, France). The composition of the suspension base is as follows: sucralose (sweetener), citric acid and sodium citrate (acidifier/buffer), modified food starch (suspending agent), sodium benzoate ( < 0.1 %, preservative), malic agent (buffer), simethicone (antifoam agent), and purified water (approximately 95 %). Methanol and acetonitrile were of HPLC grade and were procured respectively from VWR Chemicals (Fontenaysous-Bois, France) and from Fisher Chemical (IllkirchGraffenstaden, France). Water for HPLC was distilled and passed through a reverse osmosis system. Sodium hydroxide (NaOH) and hydrochloric acid (HCl) solutions used for the degradation study were purchased from Merck (Darmstadt, Germany) and oxygen peroxide (H 2 O 2 ) 10 volumes to Gifrer (Decines-Charpieu, France).
Formulations preparation
Nitrendipine oral suspension (5 mg/mL) was prepared, according to the Good Manufacturing Practices (7), using nitrendipine 20 mg tablets (Nidrel ® ) and the suspending vehicle Syrspend ® SF PH4. Tablets were ground to fine powder and combined with the vehicle. These preparations were packaged in amber glass bottles because, like most 1,4-dihydropyridines derivatives, nitrendipine shows high photosensitivity (8) (9) (10) . The products were stored at room temperature (24°C ± 1°C) because nitrendipine is not a thermolabile active ingredient [11] .
Instrumentation and chromatographic conditions
Nitrendipine concentrations of each sample were measured by HPLC with UV detection. The chromatographic system included a 515 HPLC pump, an autosampler 717plus and a 2487 UV detector (Waters, Milford, USA). The separation of the analytes was performed on a C-18 reversed phase column Atlantis T3 column (4.6 × 150 mm, 5 µm) that was kept as 25°C. The mobile phase was prepared by a mixture of methanol/water/acetonitrile (40:20:40 v/v). The injection volume of sample was 10 μL, the mobile phase flow rate was set at 1 mL/min, and detection was done at 280 nm. Data collection and analysis were performed using Empower ® Software (Waters, Milford, USA). All the HPLC equipment is available in the control laboratory of the hospital pharmacy: this facilitates the preparations' control extemporaneously.
Analytical validation
The analytical validation was performed according to the recommendations of ICH Q2R1 [3] including the assessment of system linearity, accuracy, precision (repeatability, intermediate precision) and specificity [12] . The linearity was checked for nitrendipine assay in the concentration range from 75 to 175 µg/mL (75 µg/mL, 100 µg/mL, 125 µg/mL, 150 µg/mL, 175 µg/mL). In order to check if there were interactions of excipients, two types of range were realized: one containing only the API and one reconstituted with the suspending vehicle. In summary, six different curves were performed on three different days. The method was considered as linear if the correlation coefficient was over 0.99 for the mean standard curve.
To assess the accuracy, the results obtained during the evaluation of the linearity were used. Accuracy values were obtained by calculating relative error (report between theoretical and calculated concentration) for three quality control samples (75 µg/mL, 125 µg/mL, 175 µg/mL). This report allows to access to a recovery rate. To be accepted, this rate has to be less than 5 %.
To study the repeatability of the method, six determinations of the 125 µg/mL solutions were achieved. To evaluate intermediate precision, the protocol applied to the study of repeatability was reproduced two other days by different operators. Repeatability and intermediate precision were determined using relative standard deviation and the threshold value for acceptability was 5 %.
A stability-indicating method is a method able to distinguish the API from its degradation products. The method has to be sufficiently sensitive to detect these degradation products in low quantity and sufficiently resolute to distinguish products with potentially close structures [13, 14] . Different degradative conditions were tested: alkaline, acidic, thermal and oxidative [15] . Alkaline hydrolysis was studied by adding different concentration of NaOH (0.1 M, 0.5 M, 1 M, and 12 M) in the nitrendipine solution (1:4 v/v). After one hour, neutralization was performed with respectively 0.1 M, 0.5 M, 1 M and 12 M HCl solutions. The acidic hydrolysis was performed by doing the opposite procedure. Thermal degradation was assessed by placing the solution at 80°C during 1 hour. The oxidative degradation was studied by adding a H 2 O 2 10 volumes solution to the nitrendipine solution.
Stability of oral suspension Assay
Three nitrendipine oral suspensions were prepared at day 0. Nitrendipine concentration was quantified in triplicate immediately after preparation and after 3, 7, 10, 15, 30, 60 and 90 days. Before removing samples, the containers were handshake manually to ensure a homogeneous suspension. According to the 9th edition of the European Pharmacopoeia [11], nitrendipine is practically insoluble in water and fairly soluble in methanol. For this reason, a 400 µL sample of each preparation were diluted (1:10 v/v) in methanol and centrifuged at 4000 rpm for 5 min to sediment insoluble excipients. Another dilution (1:4 v/v) of supernatant was performed in methanol in order to inject into the HPLC system. The chemical stability was determined by calculating the percentage of the initial concentration remaining at each time interval: nitrendipine concentration in subsequent samples greater than 95 % were considered stable.
In order to obtain standard solutions for HPLC analysis, a 20 mg/mL nitrendipine solution was prepared by crushing Nidrel ® 20 mg tablets and dissolving the powder into methanol. Then, this stock solution was diluted with methanol to obtain standard solutions in the range between 75 and 175 µg/mL.
pH determination
The pH of the suspension was determined initially and on each study day using a pHenomenal ® pHmeter (VWR Chemicals, Fontenay-sous-Bois, France). Three measurements were performed on each study day (one on each suspension vial). The pH was considered as stable is the variation of pH did not exceed 0.5 units.
Osmolality determination
Osmolality measurements were performed with Advanced Instruments Model 3250 osmometer (Radiometer, NeuillyPlaisance, France). Osmolality were determined in triplicate (one experiment on each suspension vial) at day 0 and on each study day. A 250 µL aliquot of each suspension were taken and diluted (1:2 v/v) in water for injection before measurement. A variation of the initial measurement less than 10 mOsm/kg was considered as stable (the precision of the osmometer was 2 mOsm/kg).
Physical stability
A visual examination was performed along the stability study in order to detect a precipitation, color change or other macroscopic manifestations (e. g. smell change). The preparation was considered physically stable if those characteristics were not changed.
Microbiological stability
According to the European Pharmacopoeia [11], the microbiological quality of oral preparations must satisfy the following tests: enumeration of total viable aerobic germs with a maximum of 10 3 bacteria and 10 2 molds and yeasts per milliliter and absence of Escherichia coli. Microbiological stability was assessed at each study day by manual counting of colony-forming units on media plates. Because the suspensions were purposed for use as a multiple dose regimen, it was necessary to determine the microbiological stability of the preparations whether they retained the quality once the containers were opened under ambient conditions. Previously, a fertility test was performed in order to ensure that one of the products present in the vehicle Syrspend SF PH4 did not inhibit microbial sprouting.
Statistical analysis/data analysis
The results are represented as the mean value of nine independent experiments ± 95 % confidence interval. All statistical tests were performed by the Excel ® software (Microsoft Office, USA, 2007) with a risk α of 5 %. Statistical significance was defined as p < 0.05.
Results
Analytical validation Linearity
Three curves were performed on three different days. The same manipulation was done without and with excipients in order to appreciate the influence of excipients on nitrendipine detection. Correlation coefficients of the standard curves were 0.9925, 0.9992 and 0.9987 for curves without excipients. Concerning curves with excipients, correlation coefficients values were 0.9977, 0.9993 and 0.9998. The difference was not statistically significant (p = 0.7804).
Accuracy
The accuracy of the method was estimated to 2.27 %, 3.86 % and 2.95 % respectively on the 75, 125 and 175 μg/mL concentrations of quality control samples. Those results were obtained using ranges with excipients.
Precision
Precision was tested on two levels: repeatability and intermediate precision. Relative standard deviation of the results was 0.93 % for the repeatability and 1.03 % for the intermediate precision.
Specificity
The retention time of nitrendipine was approximatively 3.6 min ( Figure 1A ). In this method, alkaline degradation seems to be the major route of degradation. We observed a major degradation product at 3.2 min ( Figure 1B ). The degradation product was well-resolved from the nitrendipine peak. Resolution between nitrendipine peak and the major degradation product peak identified was 1.6. This resolution value, greater than 1.5, ensures that nitrendipine and his degradation product are well separated.
Stability of oral suspension
Chemical stability
Regarding to chemical stability, the nitrendipine measured concentrations were within more or less 5 % of the nominal concentration (Table 1) .
pH and osmolality
During the whole study, all pH measurements were comprised between 4.20 and 4.27 ( Figure 2 ). No significant variation was observed. In the same way, osmolality were not modified, varying between 44 and 48 mOsm/kg ( Figure 3 ).
Physical stability
Visual inspections revealed no change in color during the studied period (all suspensions maintained their initial yellow color). No precipitation or macroscopic changes were observed.
Microbiological stability
No antimicrobial properties were observed with the suspending vehicle. Nitrendipine suspensions prepared using good manufacture practice was found to be free of germs (no colony-forming units were found during the study). Those results show that the microbiological quality of the suspensions is not impaired during the repeated opening of the bottle over a period of 90 days, allowing the manufacture of a multidose vial.
Discussion
Regarding to the method validation, all the parameters were acceptable. The method was considered as linear because the correlation coefficient was over 0.99 for the mean. No interference of the excipients was observed. Moreover, accuracy and precision were validated because values were inferior to 5 %. The method is stability indicating and reliable to detect and quantify any potential degradation in the drug product during stability studies. This proposed HPLC method was found to be simple, rapid, sensitive, precise, linear, accurate, and stability indicating. Thus, it can be used for the assay of nitrendipine during the stability study and for routine quality control analysis. For economic reasons, no pure sample of nitrendipine or degradation products was used so excipients of the specialty used can be observed in the chromatogram. Preliminary tests have showed that the suspension was homogeneous (no significant variation were observed in assays of API in the top, middle or bottom of the bottle, with and without agitation). Moreover, because a lack of Table 1 : Chemical stability of nitrendipine suspension after storage at room temperature and protected from light (n = 9).
Study day
Percent of nitrendipine initial concentration remaining ( %, confidence interval) available material, no photodegradation was tested, this could have been interesting with this photosensitive API. Along 90 days, no significant variation of the nitrendipine concentration was observed in the oral suspension. This concentration was always higher than 95 % of the initial concentration. A 95 % threshold was established because dosages in pediatrics are sometimes low and a good precision of the prepared dose is needed to ensure a good management of hypertension. Osmolality and pH were also stable along time and no macroscopic changes were highlighted. Those results are in accordance with the absence of degradation products observed in chromatograms. It would have been interesting to highlight if the appearance of degradation products cause a change in the pH of the suspension and thus induce a hydrolytic degradation of nitrendipine. To complete the physical study of this oral suspension, measurement of viscosity should be interesting. In fact, the viscosity can change either giving more fluid or, conversely, more viscous products. During this study, only the appearance and the consistency of the formulation were assessed with a visual inspection because no qualified viscometer was available in our laboratory.
Conclusion
Nitrendipine oral suspensions 5 mg/mL are stable for at least 90 days when stored at temperature room and in amber glass bottles. Indeed, pH and osmolality did not change significantly over 90 days. All the preparations retain minimum 95 % of the initial concentration after 90 days and no physical changes were highlighted. This suspension is more suitable for children than tablets and allows obtaining accurate doses based on patient's body weight.
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